"Lorlatinib Is Active in ROS1-Positive Non-Small Cell Lung Cancer."

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

In a phase I/II trial, lorlatinib was safe and effective in ROS1-positive non-small cell lung cancer. Click to show full abstract

In a phase I/II trial, lorlatinib was safe and effective in ROS1-positive non-small cell lung cancer.

Keywords: small cell; positive non; cancer; ros1 positive; cell lung; non small

Journal Title: Cancer discovery
Year Published: 2020

Link to full text (if available)

Share on Social Media: Sign Up to like & get
recommendations!
1

LAUSR

You are not signed in:

Sign Up!

Related content

More Information News Social Media Video Recommended